Gout due to xanthine derivatives.
Toda
K
K
Goriki
K
K
Ochiai
M
M
Tokunou
H
H
Uehara
S
S
Takahashi
H
H
Okusaki
K
K
D000493:Allopurinol / Q000494:pharmacology / Q000627:therapeutic use; D000628:Aminophylline / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001553:Benzbromarone / Q000494:pharmacology / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006073:Gout / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D011339:Probenecid / Q000494:pharmacology / Q000627:therapeutic use; D013806:Theophylline / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D014527:Uric Acid / Q000097:blood; D014528:Uricosuric Agents / Q000494:pharmacology / Q000627:therapeutic use
D001993:Bronchodilator Agents; D014528:Uricosuric Agents; D014527:Uric Acid; D000628:Aminophylline; D001553:Benzbromarone; D000493:Allopurinol; D013806:Theophylline; D011339:Probenecid